AIM-Harvard/TrialPanorama-filtered huggingface dataset:
Study NCT01043601 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Inhaled PT005
Description: inhaled, twice daily for 1 week duration
Study NCT01043601 — intervention group
Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Inhaled Placebo
Description: inhaled, twice daily for 1 week duration
Study NCT01043601 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Formoterol Fumarate 12 µg (Foradil Aerolizer)
Description: inhaled, twice daily for 1 week duration
Study NCT02616900 — intervention group
Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: eSight Eyewear
Description: primary intervention
Study NCT02076958 — intervention group
Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Community Health Advisor education
Study NCT02076958 — intervention group
Intervention type: BEHAVIORAL
Group type: ACTIVE_COMPARATOR
Intervention: Community Health Advisor education
Study NCT03318484 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Optimal Medical Care
Description: Aspirin 100mg once a day, Atorvastatin 20mg once a day and Antihypertensive Agents if necessary.
Study NCT03318484 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Optimal Medical Care
Description: Aspirin 100mg once a day, Atorvastatin 20mg once a day and Antihypertensive Agents if necessary.
Study NCT03318484 — intervention group
Intervention type: COMBINATION_PRODUCT
Group type: EXPERIMENTAL
Intervention: Sonodynamic therapy
Description: SDT treatment is the combination of sonosensitizer administration and target atherosclerotic lesions ultrasound exposure. Sinoporphyrin sodium (DVDMS) as sonosensitizer, is dissolved in 0.9% sodium solution for following skin test and intravenous injection. 0.01mg/ml DVDMS solution (0.1ml) is prepared for skin test followed by 0.04 mg/ml DVDMS solution intravenous injection (0.2mg/kg). The target atherosclerotic lesions are marked on the corresponding skin with ultrasound guidance and underwent ultrasound exposure after 4 hours incubation. The therapeutic ultrasonic transducer is fixed to the marked skin site for 15min of each lesion. Ultrasound parameters included intensity of 1.8W/cm2 for femoral lesions, resonance frequency: 1.0 MHz and duty factor: 30%.
Study NCT01028118 — intervention group
Intervention type: OTHER
Group type: OTHER
Intervention: Identifying experience with violence
Description: Asking about life experience with violence and Cognitive Behavior Therapy.
Study NCT00599716 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: sodium hyaluronate
Description: a sterile, unpreserved eye drop containing sodium hyaluronate in a proprietary formulation to be administered by ocular instillation
Study NCT00599716 — intervention group
Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: vehicle
Description: identical to proprietary formulation of active eye drop but without active ingredient, sodium hyaluronate
Study NCT05042024 — intervention group
Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Scaling and root planing
Description: Conventional periodontal therapy, non-surgical periodontal therapy
Study NCT05042024 — intervention group
Intervention type: PROCEDURE
Group type: ACTIVE_COMPARATOR
Intervention: Scaling and root planing
Description: Conventional periodontal therapy, non-surgical periodontal therapy
Study NCT05042024 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Oral L-arginine aspartate administration
Description: The use of L-arginine aspartate as adjuncts to local conservative treatment (scaling and root planing) of periodontitis to optimize treatment by modulating local macrophage subpopulations
Study NCT05042024 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Oral L-ornithine aspartate administration
Description: The use of L-ornithine aspartate as adjuncts to local conservative treatment (scaling and root planing) of periodontitis to optimize treatment by modulating local macrophage subpopulations
Study NCT01122901 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: gamma-secretase/Notch signalling pathway inhibitor RO4929097
Description: Given PO
Study NCT01122901 — intervention group
Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: therapeutic conventional surgery
Description: Undergo surgery
Study NCT01122901 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: pharmacological study
Description: Correlative studies
Study NCT01122901 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: laboratory biomarker analysis
Description: Correlative studies
Study NCT01093430 — intervention group
Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Anterior superior iliac spine
Description: The position of the right and left laparoscopic port sites will be determined by palpation of the nearby anterior superior iliac spine of the pelvic bone.
Study NCT01093430 — intervention group
Intervention type: PROCEDURE
Group type: ACTIVE_COMPARATOR
Intervention: Control
Description: The position of the right and left laparoscopic port sites will be determined by visual inspection of the anterior abdominal wall.
Study NCT03565796 — intervention group
Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Personalized active referral plus financial incentive
Description: Smokers will be introduced to various SC services in Hong Kong and be motivated to use the services.Written consents will be obtained from smokers who are ready to book the service onsite for transfer of their contact telephone numbers to their chosen service providers. Our research staff will transfer the information to the service providers within a week since the enrollment.Smokers are informed at baseline that they will receive financial incentive (supermarket coupon HK$300) if they attend or use any of the SC services within 3-month.
Study NCT03565796 — intervention group
Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: AWARD advice
Description: Ask about smoking history, Warn about the high risk of smoking, Advise to quit as soon as possible, Refer to the smoking cessation services, and Do it again (if the smokers refused to set quit date).
Study NCT03565796 — intervention group
Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Warning leaflet
Description: The 2-sided color printed A4 leaflet, which systematically covers the most important messages to motivate smoking cessation
Study NCT03565796 — intervention group
Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Referral card
Description: The 3-folded Smoking Cessation Services card consists of brief information and highlights of existing smoking cessation services, contact methods, motivation information and strong supporting messages or slogans
Study NCT04483778 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Pembrolizumab
Description: SCRI-CARB7H3(s)x19 plus pembrolizumab
Study NCT04922684 — intervention group
Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Mimic facial expressions
Description: 16 times (4 times a week, last 4 weeks) of mimicking facial expressions.
Study NCT04922684 — intervention group
Intervention type: BEHAVIORAL
Group type: ACTIVE_COMPARATOR
Intervention: Mimic facial expressions
Description: 16 times (4 times a week, last 4 weeks) of mimicking facial expressions.
Study NCT01947478 — intervention group
Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: MDT-2113 Drug-Eluting Balloon
Description: Subjects will be randomized (2:1) to the MDT-2113 Drug-Eluting Balloon Arm or to the standard non-coated PTA balloon Arm
Study NCT01947478 — intervention group
Intervention type: DEVICE
Group type: ACTIVE_COMPARATOR
Intervention: Standard angioplasty balloon
Description: Subjects will be randomized (2:1) to the MDT-2113 Drug-Eluting Balloon Arm or to the standard non-coated PTA balloon Arm
Study NCT05855616 — intervention group
Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Group chlorhexidine dressing
Description: Cleaning of the exit site with physiological saline (0.9%), drying with sterile gauze, application of semi-permeable polyurethane dressing with self-adhesive 2% chlorhexidine gluconate, centring the chlorhexidine gluconate band well over the exit site.
Study NCT05855616 — intervention group
Intervention type: OTHER
Group type: OTHER
Intervention: Group solution
Description: Cleansing of the exit site with physiological saline (0.9%), drying with sterile gauze, disinfection with 2% aqueous-based chlorhexidine solution, environmental drying for 30 seconds and covering with a semi-permeable self-adhesive polyurethane dressing.
Study NCT02251119 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Tipranavir
Study NCT02251119 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Ritonavir
Study NCT02251119 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Loperamide
Study NCT05334355 — intervention group
Intervention type: OTHER
Intervention: Family history of hypertension
Description: Presence or absence of a family history of hypertension in a cross sectional study design.
Study NCT03916991 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Exercise
Description: Hip focused Neuromuscular Activation Exercise
Study NCT03916991 — intervention group
Intervention type: OTHER
Group type: SHAM_COMPARATOR
Intervention: Exercise
Description: Hip focused Neuromuscular Activation Exercise
Study NCT01617200 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Asenapine
Description: 2.5 mg or 5 mg fast dissolving active asenapine tablets administered sublingually, same number of tablets are taken in the morning and the evening
Study NCT04535752 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: ANX009
Description: Single or multiple ascending dose
Study NCT04535752 — intervention group
Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: Single or multiple ascending dose
Study NCT05052242 — intervention group
Intervention type: DIAGNOSTIC_TEST
Intervention: primary angle closure disease
Description: 2 swept source OCT biometers, IOL Master700 and Anterion
Study NCT03065595 — intervention group
Intervention type: DIETARY_SUPPLEMENT
Group type: PLACEBO_COMPARATOR
Intervention: Ophiochepalus striatus extract
Description: each sachet of ophiochepalus striatus extract is poured into 50 mL normal water and drink two times/day
Study NCT03065595 — intervention group
Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: Placebo
Description: each sachet of placebo drug is poured into 50 mL normal water and drink two times/day
Study NCT03169920 — intervention group
Intervention type: PROCEDURE
Group type: ACTIVE_COMPARATOR
Intervention: Modified-Minimally Invasive Surgical Technique + PRF
Study NCT03169920 — intervention group
Intervention type: PROCEDURE
Group type: ACTIVE_COMPARATOR
Intervention: Modified-Minimally Invasive Surgical Technique
Study NCT00730054 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Remifentanil+clonidine
Description: iv Remifentanil+ iv clonidine
Study NCT00730054 — intervention group
Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Remifentanil+clonidine
Description: iv Remifentanil+ iv clonidine
Study NCT00730054 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Remifentanil+clonidine
Description: iv Remifentanil+ iv clonidine
Study NCT02167542 — intervention group
Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Noninvasive Positive Pressure Ventilation
Description: Patients assigned to NPPV were connected to the ventilator through a face mask (VBM Endoscopy Mask) that was secured to the patient's face by the investigator. Only one type of mechanical ventilator will be used (Vision, Philips Respironics). Ventilator parameters and supplemental oxygen will be titrated by the investigator to achieve SpO2>92%. Ventilatory support via face mask will be maintained with the same pressures for at least 30min after FOB, and then will be replaced by the FIO2 mask's if needed.
Study NCT02167542 — intervention group
Intervention type: DEVICE
Group type: ACTIVE_COMPARATOR
Intervention: CPAP valve (Boussignac)
Description: Patients assigned to CPAP Boussignac valve are connected to this device through a face mask that is secured to the patient's face with elastic straps. This kind of CPAP allows the delivery of pressure by constant-flow oxygen insufflation. Four funnel-shaped microchannels are included in the wall of this device and connected to an external opening connected to the oxygen source. These microchannels generate high-velocity microjets, which in turn generate the pressure resulting from the air entrainment mechanism thus created.~Oxygen flow will be titrated by the investigator to ensure SpO2>92%.
Study NCT03331380 — intervention group
Intervention type: DEVICE
Group type: OTHER
Intervention: MRI scan - obj 1
Description: For objective 1 (protocol optimization), healthy volunteers undergo imaging using an investigational low SAR CMR scanner for up to two hours, some without and some with administration of intravenous gadolinium based contrast agents (GBCAs).
Study NCT03331380 — intervention group
Intervention type: DEVICE
Group type: OTHER
Intervention: MRI scans - obj 2
Description: For objective 2 (comparative scanning of normals), healthy volunteers undergo two CMR examinations on two different MRI scanners (investigational low SAR CMR and conventional 1.5T CMR), some without and some with administration of intravenous GBCA.
Study NCT01617200 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Placebo Asenapine
Description: 2.5 mg or 5 mg fast dissolving placebo asenapine tablets administered sublingually, same number of tablets are taken in the morning and the evening
Study NCT01617200 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Olanzapine
Description: 15 mg film-coated active olanzapine tablets administered orally QD. The time of the active olanzapine dose (either morning or evening) is not disclosed in order to preserve blinding.
Study NCT01617200 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Placebo Olanzapine
Description: 15 mg film-coated placebo olanzapine tablets administered orally QD. The time of the active olanzapine dose (either morning or evening) is not disclosed in order to preserve blinding.
Study NCT01617200 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Placebo Olanzapine
Description: 15 mg film-coated placebo olanzapine tablets administered orally QD. The time of the active olanzapine dose (either morning or evening) is not disclosed in order to preserve blinding.
Study NCT03565796 — intervention group
Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: COSH booklet
Description: A general smoking cessation self-help booklet
Study NCT00736424 — intervention group
Intervention type: DEVICE
Intervention: Itrel II™ and Soletra™ Epilepsy Control System
Description: Bilateral neurostimulation of the anterior nucleus of the thalamus
Study NCT03884959 — intervention group
Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: HepaStem Infusion
Description: HepaStem will be infused intravenously into the portal vein, either (1) via a permanent mesenteric PAC inserted surgically in an affluent of the portal vein; or (2) through a transient percutaneous transhepatic catheter inserted in to the portal vein under radio guidance.
Study NCT03142178 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Experimental: 3VM1001 active 2g Cream 3 times daily
Description: 3VM1001 2g Cream with active ingredient administered 3 times daily
Study NCT03142178 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Experimental: 3VM1001 active 3g Cream 3 times daily
Description: 3VM1001 3g Cream with active ingredient administered 3 times daily
Study NCT03142178 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Experimental: 3VM1001 active 3g Cream 4 times daily
Description: 3VM1001 3g Cream with active ingredient administered 4 times daily
Study NCT03142178 — intervention group
Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo: 3VM1001 vehicle 2g Cream 3 times daily
Description: 3VM1001 placebo 2g vehicle Cream administered 3 times daily
Study NCT00965055 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Ezetimibe
Description: 10 mg
Study NCT03142178 — intervention group
Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo: 3VM1001 vehicle 3g Cream 3 times daily
Description: 3VM1001 placebo 3g vehicle Cream administered 3 times daily
Study NCT03142178 — intervention group
Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo: 3VM1001 vehicle 3g Cream 4 times daily
Description: 3VM1001 placebo 3g vehicle Cream administered 4 times daily
Study NCT02225561 — intervention group
Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: pharmaco- mechanical optimization
Description: Getting started as soon as possible cardiopulmonary resuscitation (CPR) mechanical ( LUCAS 2) with inspiratory impedance valve ( ResQPOD ) performed according to the 2015 recommendations of the European Resuscitation Council . It will be carried out continuously without a break for control pulse until the first defibrillation attempt.~As soon the peripheral intravenous or intraosseous line is set the intervention group will receive an injection of 2 mg of sodium nitroprusside. 4 minutes after the first injection, a second and last injection of 1 mg of sodium nitroprusside will be realized.- The preparation procedure of the sodium nitroprusside will be:~* Using a pomping needle and the provided syringe 4 ml of the solvent (Water for Injections, WFI) will be take.~* The 4 ml of WFI will be empty in the 50 mg vial of lyophilisate sodium nitroprusside to solubilize the product.~* Always with the needle and 20 ml syringe, the 4 ml of this solution (50 mg in 4 ml) will be collect.
Study NCT02225561 — intervention group
Intervention type: PROCEDURE
Group type: ACTIVE_COMPARATOR
Intervention: mechanical optimization only
Description: Getting started as soon as possible cardiopulmonary resuscitation (CPR) mechanical ( LUCAS 2) with inspiratory impedance valve ( ResQPOD ) performed according to the 2015 recommendations of the European Resuscitation Council . It will be carried out continuously without a break for control pulse until the first defibrillation attempt.
Study NCT02362269 — intervention group
Intervention type: DIETARY_SUPPLEMENT
Group type: ACTIVE_COMPARATOR
Intervention: Vitamin D
Description: Gelcaps containing 1000, 2500, and 4000 IU of vitamin D3 will be obtained from Tischon corporation (Westbury, NY). The gelcaps will be protected from light and not stored above 25° C. Participants will be instructed to take their vitamin D3 gelcaps with supper daily. Compliance with study supplementation will be documented by pill count at the time of each study visits.
Study NCT02362269 — intervention group
Intervention type: DIETARY_SUPPLEMENT
Group type: EXPERIMENTAL
Intervention: Vitamin D
Description: Gelcaps containing 1000, 2500, and 4000 IU of vitamin D3 will be obtained from Tischon corporation (Westbury, NY). The gelcaps will be protected from light and not stored above 25° C. Participants will be instructed to take their vitamin D3 gelcaps with supper daily. Compliance with study supplementation will be documented by pill count at the time of each study visits.
Study NCT03461978 — intervention group
Intervention type: DEVICE
Group type: OTHER
Intervention: Ultrahigh resolution Spectral Domain OCT
Description: A spectrometer based ultrahigh resolution Spectral Domain OCT (SDOCT) system operating at 800 nm for the anterior chamber will be employed in the present study. The spectrum of the Ti:Sapphire laser light source is centered at 800 nm. With a full width at half maximum bandwidth of 170 nm, the axial resolution is 1.3 μm in the cornea. The transverse resolution of the employed OCT system is 21 μm at the front surface of the cornea. For measurement, patients will place their head in a modified slit lamp head rest. During the measurement period, patients will be asked to look straight forward onto an internal fixation target and to avoid blinking. Different scattering patterns, e.g. raster, circular and spiral scans will be employed.
Study NCT00431769 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Bortezomib
Description: Bortezomib will be given intravenously (into a vein) twice weekly, on Days 1, 4, 8 and 11 and then a 10-day (Days 12 to 21) rest period, of each 3-week cycle for up to a total of 8 cycles. The initial bortezomib dose is 1.0 or 1.3 milligram per meter square (mg/m\^2) depending on the previous bortezomib-based treatment, up to a maximum dose of 1.3 mg/m\^2. Participants will receive bortezomib in combination with or without dexamethasone, in accordance with the standard of care. The median total dose of dexamethasone per cycle ranges from 120 mg (Cycle 7) to 160 mg (Cycles 1 to 6 and 8).
Study NCT00965055 — intervention group
Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Atorvastatin
Description: Visit 1: (atorvastatin open label challenge): Those who complete the initial screening and washout period will receive open label atorvastatin 10 mg daily for 6 weeks to verify compliance and confirm hyporesponse to statin therapy.~Visit 2: After 6 weeks of therapy repeat baseline fasting cholesterol. Those with LDL-c reduction of 25% or less will be able to proceed to next phase. Patients with greater than 25% LDL-C reduction will be excluded. We expect to randomize 80 patients~Visit 2a: Dispensing of first randomized drug allocation- all patients receive open label atorvastatin 10 mg with additional ezetimibe 10 mg or matching placebo. No blood test during this visit.~Visit 3, 4, 5: Dose titration to atorvastatin to 20 mg, 40 mg, 80 mg, respectively, after fasting blood test~Blood collected in visits 3, 4, and 5 will be stored for additional tests regarding cholesterol metabolism and inflammation.~Visit 6: Final cholesterol panel and conclusion of study period
Study NCT00965055 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Atorvastatin
Description: Visit 1: (atorvastatin open label challenge): Those who complete the initial screening and washout period will receive open label atorvastatin 10 mg daily for 6 weeks to verify compliance and confirm hyporesponse to statin therapy.~Visit 2: After 6 weeks of therapy repeat baseline fasting cholesterol. Those with LDL-c reduction of 25% or less will be able to proceed to next phase. Patients with greater than 25% LDL-C reduction will be excluded. We expect to randomize 80 patients~Visit 2a: Dispensing of first randomized drug allocation- all patients receive open label atorvastatin 10 mg with additional ezetimibe 10 mg or matching placebo. No blood test during this visit.~Visit 3, 4, 5: Dose titration to atorvastatin to 20 mg, 40 mg, 80 mg, respectively, after fasting blood test~Blood collected in visits 3, 4, and 5 will be stored for additional tests regarding cholesterol metabolism and inflammation.~Visit 6: Final cholesterol panel and conclusion of study period